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Table 1. Patient and Product Characteristics
Transplant Variable
Ethnically
Matched
Ethnically
Mismatched
Ethnic Group
Recipient Donor
Caucasian Caucasian 97.1%
Poster Session II S353can aid in the early detection of relapsing leukemia, especially when
leukemia-specific mutation assays are not available. Detection of in-
creasing recipient-origin (mixed) chimerism may be useful in deci-
sions to alter immunosuppression, to administer donor lymphocyte
infusions, or for other treatment changes.
Previous reports showed complete chimerism correlated well with
overall survival and negatively with relapse probability. In the U.S.,
detection of chimerism is performed using PCR for variable number
or short tandem repeats, followed by fragment separation by capil-
lary electrophoresis, resulting in poor sensitivity below 10% recipi-
ent DNA due to the imprecision of measurements of areas under the
peaks in fragment separation, as well as problematic stutter artifacts.
The higher sensitivity of detection of chimerism provided by the
real-time PCR assay could be beneficial in allowing for earlier detec-
tion of increasingmixed chimerismwith the proviso that the assay be
performed at an optimal frequency for the underlying type of
leukemia.
Previous real-time PCR assays for chimerism were not able to de-
tect an informative marker for the ‘‘recipient’’ in all ‘‘donor/recipi-
ent’’ pairs due to insufficient numbers of markers. Our assay of 28
marker loci detected at least one informative marker (IM) in 754 of
756 directional combinations of DNAs (99.7%), with an average of
5.1 markers per pair. In a subset of 28 first-degree relative pairs,
one or more IMs were found in 27 pairs (96.4%), with an average
of 3.5 IM/pair. Linearity of markers was examined by dilution of
DNA from an IM+ donor in IM-DNA. All markers showed linearity
with good PCR efficiency values. A single copy gene was used for
normalizing the % chimerism with a DDCt method using simulated
post-transplant samples (mixtures of DNAs) relative to the pre-
transplant samples (100% recipient DNAs). The % chimerism cal-
culated from DNA dilution series showed linearity with precision
down to at least 0.1% recipient DNA. The calculated % chimerism
was compared to the nominal value for determinations of accuracy
and equivalence of readout between different markers. Inter-assay
variability over three days and between three markers was demon-
strated to meet acceptance criteria.African American African American 2.2%
Asian Asian 0.6%
Hispanic/Latino Hispanic/Latino 0.2%
Caucasian Other 10.9%
Asian Other 8.2%
African American Other 26.6%
Hispanic/Latino Other 52.7%
Multi-Race Other 1.6%
Transplant Type
Single 477 161
Dual 47 8
HLA Match*
<5/6 168 86
$5/6 356 83
Gender*
Male 271 105
Female 242 61
Patient Age
N 524 169
Median (y) 7.8 6.2
Patient Weight
N 524 169
Median (kg) 25.6 21.5
TBI
Yes 264 81
No 231 75
Conditioning Regimen*
Non-Myeloablative 139 71
Myeloablative 365 94
TNC Dose
N 525 169
Median (107/kg) 6.4 6.8
CD34 Dose
N 521 168
Median (105/kg) 2.6 3.0
CFU Dose
N 521 168
Median (105/kg) .39 .39
*Denotes p values <.05.403
SURVIVAL AFTER ALLOGENEIC TRANSPLANT FOR RELAPSED LEUKEMIA
FOLLOWING CYCLOPHOSPHAMIDE, ETOPOSIDE, AND TOTAL BODY RA-
DIATION (TBI) WITH LUNG SHIELDING: INFLUENCE OF cGVHD ON RE-
LAPSE AND LUNG SHIELDING ON PULMONARY COMPLICATIONS
Morris, J.1, Morris, C.L.1, Loredo, L.2 1Loma Linda University Medical
Center, Loma Linda, CA; 2Loma Linda UniversityMedical Center, Loma
Linda, CA
Background: High dose chemotherapy and allogenic stem cell
transplant is used to consolidate relapsed leukemia. GVT is an im-
portant component of curing leukemia in this setting and GVHD
and TBI are important causes of toxicity, most notably late lung
complications. We have employed lung shielding to reduce pulmo-
nary complications in long term survivors of SCT.We report the im-
pact of cGVHD on relapse and the incidence of late lung
complications in these patients.
Method: Thirty-three patients with ALL (24), AML (8), and NHL
(1) in CR2 (28), and . or equal to CR3 (5) received allogeneic
PBSCT. Graft source was unrelated (20), HLA mismatched related
(1), or HLA identical sibling donor (12). All received 1200 cGy TBI,
etoposide 1500mg/m2, and cyclophosphamide 120mg/kg. Unre-
lated or mismatched related stem cell recipients also received ATG
(90mg/kg over 3 days). TBI was delivered in 200cGy fractions twice
daily for 3 days with double lung blocks to reduce lung dose to
300cGy. The chest wall was boosted with electrons to 1200cGy.
GVHD prophylaxis was cyclosporin for matched siblings or tacroli-
mus (all others) and short course methotrexate (10mg/M2 days 1, 3,
6, and 11 except 1 recipient of cord blood who received steroids).
Result:OS andDFSwere 19/33 (actuarial 53%) and 17/33 with me-
dian time from transplant of 41 and 47 months. For patients.1 and
.4 years from transplant, TRMwas 4/28 at 1 year and 4/15 at year 4.
Relapse for patients.1 year from transplant was 7/28 (6/11matched
sibling, 1/16 unrelated, 0/1 mismatched related donor). All relapses
occurred\1 year after transplant except 1 (21 month). The relapse
rate for sibling transplants complicated by cGVHD was 0/4 (all sur-
vived at least 1 year) and was 6/7 for sibling transplants with nocGVHD. The relapse rate for recipients of unrelated PBSC grafts
was 1/12 with 10/12 complicated by cGVHD. Of the 14 patients
with cGVHD it has resolved in 4, requires continued treatment in
5, 2 died of complications from cGVHD, and 1 relapse. There was
one case of idiopathic pneumonitis in a sibling donor transplant oc-
curring within 50 days of transplant. Among 20 patients surviving at
.1 year after transplant there is 1 case of severe restrictive lung dis-
ease due to chest wall contractures from cGVHD.
Conclusion: 1. The best predictor of DFS in this series was presence
of cGVHD. 2. GVHD was the strongest predictor of TRM. 3. Late
pulmonary complications were rare.
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EFFECTIVENESS OF UNRELATED ALLOGENEIC UMBILICAL CORD BLOOD
TRANSPLANTATION FOR ETHNICALLY MATCHED AND MISMATCHED PA-
TIENT POPULATIONS
Wofford, J.1, Sander, J.1, Stocker, A.1, Regan, D.1, Bhatla, D.2 1The St.
Louis Cord Blood Bank, St. Louis, MO; 2St. Louis University School of
Medicine, St. Louis, MO
Allogeneic hematopoietic stem cell transplantation (HSCT) has
become the accepted treatment for many life threatening hemato-
logic diseases. Outcomes are superior when HLA matched related
donors are the stem cell source for allogeneic HSCT. However,
only 15-20% of patients needing a marrow or blood cell transplant
S354 Poster Session IIhave amatched related donor.While transplant outcomes withHLA
matched unrelated donors continue to improve, this requires strin-
gent HLA matching which puts ethnic minorities at a disadvantage.
In this scenario, umbilical cord blood (UCB) has proven to be a valu-
able alternative source of hematopoietic stem cells as it allows for
successful engraftment and decreased GVHD for a greater degree
of HLA disparity. This is of particular importance for the Hispanic
and African American populations in theUnited States who often re-
ceive ethnically mismatched products due to low representation in
the donor pool despite increased recruitment efforts.
The St. Louis Cord Blood Bank (SLCBB) retrospectively evalu-
ated outcomes for 727 patients based on recipient/donor ethnic
match. 543 (74.7%) patients were matched and 184 (25.3%) were
not ethnically matched. Ninety two percent of all patients received
singleton cord blood transplant and 8 percent received dual cord
blood transplant with both products shipped from the SLCBB. Pa-
tient and product characteristics are presented in Table 1.
There were no differences between the groups with respect to ex-
posure to TBI, TNC dose/kg, CD34 dose/kg, and CFU dose/kg.
There was also no correlation between groups with respect to inci-
dence and severity of acute and chronic graft versus host disease
(p..05). Although the ethnically matched group had a higher degree
of HLAmatch (p\.05) time to neutrophil recovery was not impacted
(p..05; median days matched5 22, median days unmatched5 20).
Survival did not differ between the groups at 100 day and $ 1 year
time points (p..05).
This analysis supports the continued use of UCB as a source of he-
matopoietic reconstitution for all populations.
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IV BUSULFAN BASED CONDITIONING REGIMEN FOR HAPLOIDENTICAL
TRANSPLANTATION
Gayoso, J., Balsalobre, P., Serrano, D., Kwon,M., Bu~no, I., Rodriguez, G.,
Anguita, J., Perez Corral, A., Dıez-Martın, J.L. HGU Gregorio
Mara~non, Madrid, Spain
Introduction: Haploidentical transplant (HAPLO) offers the op-
portunity for a cure to those patients without any other available do-
nor. Following Luznik L et al experience (BBMT 2008; 14:641-650)
with a non-myeloablative schemawhere relapses were themain issue,
we developed our own conditioning model using IV busulfan (3,2
mg/kg on day -3) instead of 200cGy TBI, while maintaining post-
transplant high dose cyclophosphamide for GVHD prophylaxis on
days +3 and +4 followed by cyclosporine and MMF. Due to encour-
aging results with our initial experience, IV busulfan was increased to
3,2 mg/kg/day for 2 days in order to reduce relapse incidence and not
to increase transplant related morbidity and mortality (TRM).
Patients and Methods: From Dec-2007, 12 patients (9 males, me-
dian age 39y range 19-55) have received an HAPLO at our institu-
tion for the treatment of AML (3), ALL (1), MDS (1) Myeloma (2)
or Hodgkin’s disease (5), all of them in advanced phases of their dis-
eases. The conditioning regimen consisted of Fludarabine 30mg/m2
for 5 days, Cyclophosphamide 14,5mg/kg for 2 days and IVBusulfan
3,2 mg/kg for 1 day was used in 7 patients and 3,2 mg/kg for 2 days in
the last 5. Bone marrow was the source of progenitors in 10 and
GCSF mobilized peripheral blood without T-depletion in 2. Eight
had received a previous autologous (6) or umbilical cord blood trans-
plant (2, 1 after graft failure).
Results: Median follow up is 12.5 months (0.5-31mo). All patients
engrafted properly. Toxicities of the conditioning regimen included
grade1-2 mucositis (9) and infections (febrile neutropenia and CMV
reactivations in 11, and 1 Pseudomona vulvar cellulitis). Only 1 pa-
tient died from toxicity before day +100 (VOD/MOFat +15d, refrac-
tory ALL). AcuteGVHDgrade II-IV affected to 4/11 patients, being
grade III-IV in 2. Only 2 out of 8 cases at risk developed chronic
GVHD that was extensive in 1. After a median time of 6.5 mo
(2.5-30 mo), 7 patients are in continuous remission and 2 patients
are alive in relapse. Two patients died beyond 1 year: 1 progressive
multifocal leukoencephalopaty at +14 mo and relapse and progres-
sion of AML at +19 mo, respectively.
Conclusions: In our limited experience, IV Busulfan was well toler-
ated as part of the conditioning regimen for HAPLO. A potential re-
duction in relapse incidence without an increase in TRM would be
obtained by this approach. HAPLO is a good chance for rescueing
patients in graft failure after cord blood transplant.406
REAL-TIME QUANTITATIVE-PCR (qrt-PCR) USING AlleleSEQR TECHNOL-
OGY: TO ASSESS CHIMERISM IN PEDIATRICS PATIENTS UNDERGOING
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Khan, S.1, Olszewski, M.1, Huang, W.1, Kletzel, M.1,2 1Children’s Me-
morial Hospital, Chicago, IL; 2Northwestern University Feinberg School
of Medicine, Chicago, IL
Post-transplantation chimerismmonitoring in HSCT is pivotal to
assess engraftment, rejection or relapse. There has been previous
studies performed using qrt-PCR to detect chimerism by different
technologies. Our purpose is to describe qrt-PCR as a sensitive
and reproducible method to assess chimerism using AlleleSEQR
(Cellera). A total of 112 peripheral blood samples were obtained
from 43 allogeneic HSCT. qrt-PCR (Applied Biosystems 7500)
was performed using 34 alleles that are designed to be a bi-allelic in-
sertion/deletion (indel) polymorphism in the human genome. Ex-
traction of DNA was performed using QIAamp DNA Blood Mini
Kit (Qiagen) of both donor and recipient cells pre transplant (n 5
43) then were screened for their informative alleles. At least 2 alleles
were chosen that amplified with a CT value less than 34.0, but greater
than or equal to 30.0 with aDCT of -2.0 to +2.0. Post transplant sam-
ples (n5 69) were then separated in three subsets: TotalWBC using
the Erythrocyte Lysis Buffer (Qiagen), T-cell and Myeloid cells us-
ing RosetteSep T-cell and Myeloid Enrichment kits (Stem Cell
Technologies) followed by DNA extraction and quantitation using
the chosen informative alleles. To determine the sensitivity a serial
dilution curve is shown in Table 1 with a r 5 1. Reproducibility
was validated by a reference lab using 18 unknown samples with
a correlation of r 5 0.98. Subset analysis was reported as percent
donor total: 91.9 6 2.22, median 99.6 (35.5-100), T-cell: 93.7 6
2.56, median 99.6 (29.6-100), myeloid: 91.2 6 3.23, median 99.9
(9.30-100) with a p value of\ 0.0001. Results indicate that the use
of this technology is reproducible, sensitive and accurate to assess
donor Chimerism in pediatric patients undergoing HSCT.
Table 1. qrt-PCR Sensitivity Determination
Serial Dilution qrt-PCR Results0.1% 0.086%
0.2% 0.16%
1% 1.0%
2% 1.9%
10% 9.2%407
RAPID IDENTIFICATION OF INFORMATIVE MARKERS FROM MULTIPLE
DONORS FOR STEM CELL TRANSPLANT ENGRAFTMENT MONITORING
Sigua, C.L., Santini, C.D., Bost, D.A. Celera Corporation, Alaemda, CA
Wehave designed a system of RUOqPCR assays and software en-
abling highly sensitive, stem cell engraftment monitoring. Our ap-
proach allows for facile quantification of minute amounts of minor
components in a mixture, while also reducing workflow and analysis
burdens. This approach expands the linear dynamic range over
which increasing mixed chimerism may be monitored, effectively in-
creasing the probability of detecting adverse transplant events ear-
lier.
We utilize a panel of 34 qPCR research assays to bi-allelic indels
across the genome. Our system affords rapid pre-transplant marker
identification and quantification of recipient levels post-transplant.
It enables marker identification and quantification to occur within
a few hours and without the need for capillary electrophoresis. In
an effort to decrease our current sample volume requirements, in-
crease throughput and enable multiple donor screening scenarios,
we evaluated a multiplexed assay approach for marker identification.
The qPCR assays are multiplexed, with 2-3 assays per well. The
probes are labeled with FAM-BHQ1, California Orange-BHQ1
and Quasar 670-BHQ2. The presence of alleles is scored in relation
to amplification of an endogenous control assay. The results of sam-
ples within a group are compared against each other to identify infor-
mative markers for each sample. Up to eight samples can be
